HDAC family: What are the cancer relevant targets?

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Histone deacetylases (HDACs): characterization of the classical HDAC family

RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234

A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p

Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis

Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

Yang, X., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,277

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.

Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,198

Histone Deacetylase Inhibitors: Overview and Perspectives

Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,194

HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor

Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153

Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation

Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

McKinsey, T. A., Zhang, C., Lu, J., & Olson, E. N. (2000) · Nature · doi:10.1038/35040593 · Cited by 1,051

Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy

Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973

Deacetylation of p53 modulates its effect on cell growth and apoptosis

Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. J. (2000) · Nature · doi:10.1038/35042612 · Cited by 838

Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis

Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 805

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755

Untitled work

(2002) · PubMed · Cited by 732

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractilityPreprint

Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 716

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 696

Class II histone deacetylases: versatile regulators

Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638

HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription

Rundlett, S. E., Carmen, A. A., Kobayashi, R., Bavykin, S. G., Turner, B. M., & Grunstein, M. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14503 · Cited by 618

Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development

Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 612

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 603

Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559

Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1

Gui, C., Ngo, L., Xu, W., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550

p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells

Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 534

Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.

Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 516

Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer

Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 515

Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5

Vega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., & McKinsey, T. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8374-8385.2004 · Cited by 512

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 504

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Stephan, C., Jung, K., Fritzsche, F., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 478

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity

Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floß, T., Göttlicher, M., Ruíz, P., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 469

Untitled work

(2003) · PubMed · Cited by 465

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Garcia‐Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J. E., Wierda, W. G., Faderl, S. H., Koller, C. A., Morris, G., Rosner, G. L., et al. (2007) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 461

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458

MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development

Arnold, M., Kim, Y., Czubryt, M. P., Phan, D., McAnally, J., Qi, X., Shelton, J. M., Richardson, J. A., Bassel‐Duby, R., & Olson, E. N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.02.004 · Cited by 456

Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10

Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006) · Cell · doi:10.1016/j.cell.2006.05.040 · Cited by 454

The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress responsePreprint

Kwon, S., Zhang, Y., & Matthias, P. (2007) · Genes & Development · doi:10.1101/gad.461107 · Cited by 417

Vorinostat

Grant, S., Easley, C., & Kirkpatrick, P. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 417

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Ryan, Q. C., Headlee, D. J., Acharya, M. R., Sparreboom, A., Trepel, J. B., Ye, Z., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 412

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 401

Histone deacetylase 8 in neuroblastoma tumorigenesis

Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398

Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes

Huang, Y., Myers, S. J., & Dingledine, R. J. (1999) · Nature Neuroscience · doi:10.1038/13165 · Cited by 397

NuRD and SIN3

Ahringer, J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02066-7 · Cited by 388

The histone deacetylase-3 complex contains nuclear receptor corepressors

Wen, Y.-D., Perissi, V., Staszewski, L. M., Yang, W.-M., Krones, A., Glass, C. K., Rosenfeld, M. G., & Seto, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7202 · Cited by 378

Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control

Bhaskara, S., Chyla, B., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 369

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 368

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

Weichert, W., Roske, A.-E., Niesporek, S., Noske, A., Buckendahl, A., Dietel, M., Gekeler, V., Boehm, M., Beckers, T. L., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 362

Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues

Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S., Joo, H. J., & Kim, D.-Y. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 351

Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases

Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R. B., Zhang, G., Johanson, K., Liu, R., Lago, A. M., Hofmann, G. A., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 350

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

Huang, B., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto‐Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337

ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain

Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B. A., Harada, H., Lenny, N. T., Downing, J. R., Meyers, S., & Hiebert, S. W. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.19.6470-6483.2001 · Cited by 336

Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α

Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. W., & Пили, Р. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 308

Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 307

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setién, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 300

HDAC6 Expression Is Correlated with Better Survival in Breast Cancer

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 295

Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1

Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J. T., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 283

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Gojo, I., Jiemjit, A., Trepel, J., Sparreboom, A., Figg, W., Rollins, S., Tidwell, M. L., Greer, J., Chung, E., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281

HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions

Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281

Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.

Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y., et al. (2000) · PubMed · Cited by 273

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks

Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271

SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes

Berdeaux, R., Goebel, N., Banaszynski, L. A., Takemori, H., Wandless, T. J., Shelton, G. D., & Montminy, M. (2007) · Nature Medicine · doi:10.1038/nm1573 · Cited by 270

Differential expression of selected histone modifier genes in human solid cancers

Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G. J., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 266

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S.-I., Ito, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 266

Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation

Senese, S., Zaragoza, K., Minardi, S. P., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 253

Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

Piekarz, R., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 233

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A. J., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 231

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

Jaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 224

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 220

Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors

KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E. M., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 195

Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis

Mottet, D., Bellahcène, A., Pirotte, S., Waltregny, D., Deroanne, C., Lamour, V., Lidereau, R., & Castronovo, V. (2007) · Circulation Research · doi:10.1161/circresaha.107.149377 · Cited by 192

Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides

Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 185

Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma

Sakuma, T., Uzawa, K., Onda, T., Shiiba, M., Yokoe, H., Shibahara, T., & Tanzawa, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.117 · Cited by 185

Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal Transition

Shan, B., Yao, T., Nguyen, H. T., Zhuo, Y., Levy, D. R., Klingsberg, R. C., Tao, H., Palmer, M. L., Holder, K. N., & Lasky, J. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802786200 · Cited by 176

HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization

Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T., & Comb, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c700185200 · Cited by 174

Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma

Rikimaru, T., Taketomi, A., Yamashita, Y., Shirabe, K., Hamatsu, T., Shimada, M., & Maehara, Y. (2007) · Oncology · doi:10.1159/000111106 · Cited by 172

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171

Crystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue

Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A., & Ficner, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.065 · Cited by 157

Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma

Miyake, K., Yoshizumi, T., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., & Shimada, M. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815f2c2a · Cited by 156

Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity

Harms, K. L., & Chen, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4397 · Cited by 156

Histone deacetylase 1 mRNA expression in lung cancer

Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Kiriyama, M., Fukai, I., Yamakawa, Y., & Fujii, Y. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.021 · Cited by 144

Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells

Bruserud, Ø., Stapnes, C., Ersvær, E., Gjertsen, B. T., & Ryningen, A. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018417 · Cited by 141

Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin

Sternson, S. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2001) · Organic Letters · doi:10.1021/ol016915f · Cited by 139

Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice

Zimmermann, S., Kiefer, F., Prudenziati, M., Spiller, C., Hansen, J., Floß, T., Wurst, W., Minucci, S., & Göttlicher, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0312 · Cited by 132

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

Inoue, S., Mai, A., Dyer, M. J. S., & Cohen, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4563 · Cited by 131

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130

Functional Differences in Epigenetic ModulatorsSuperiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies

Kozikowski, A. P., Chen, Y., Gaysin, A. M., Chen, B., D’Annibale, M. A., Suto, C. M., & Langley, B. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070178x · Cited by 123

Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter

Wu, L., Wang, X., Li, L., Zhao, Y., Lu, S., Yu, Y., Zhou, W., Liu, X., Yang, J., Zheng, Z., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01516-07 · Cited by 122

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 117

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 117

An expression screen reveals modulators of class II histone deacetylase phosphorylation

Chang, S., Bezprozvannaya, S., Li, S., & Olson, E. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503275102 · Cited by 108

Design, Synthesis, Structure−Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors

Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7009217 · Cited by 106

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060554y · Cited by 105

Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide

Keshelava, N., Davicioni, E., Wan, Z., Ji, L., Sposto, R., Triche, T. J., & Reynolds, C. P. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm044 · Cited by 102

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

Park, J., Kim, S.-H., Choi, M.-C., Lee, J., Oh, D., Im, S., Bang, Y., & Kim, T.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.056 · Cited by 98

Inhibition of histone deacetylase1 induces autophagy

Oh, M., Choi, I.-K., & Kwon, H. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.019 · Cited by 97

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97

Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation

Watamoto, K., Towatari, M., Ozawa, Y., Miyata, Y., Okamoto, M., Abe, A., Naoe, T., & Saito, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206902 · Cited by 95

Genetic variants in epigenetic genes and breast cancer risk

Cebrián, A., Pharoah, P. D. P., Ahmed, S., Ropero, S., Fraga, M. F., Smith, P. L., Conroy, D. M., Luben, R., Perkins, B., Easton, D. F., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi375 · Cited by 95

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93 · cited 1×

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Arts, J., Angibaud, P. R., Mariën, A., Floren, W., Janssens, B., King, P., Dun, J. V., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 89

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor–Mediated Signaling

Biçaku, E., Marchion, D. C., Schmitt, M. L., & Münster, P. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2822 · Cited by 89

Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation

Lee, H., Sengupta, N., Villagra, A., Rezai‐Zadeh, N., & Seto, E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01971-05 · Cited by 86

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report

Fouladi, M., Furman, W. L., Chin, T. K., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82

HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF

Chauchereau, A., Mathieu, M., de Saintignon, J., Ferreira, R., Pritchard, L. L., Mishal, Z., Dejean, A., & Harel‐Bellan, A. (2004) · Oncogene · doi:10.1038/sj.onc.1208128 · Cited by 78

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors

JONES, P. G., Bottomley, M. J., Carfı́, A., Cecchetti, O., Ferrigno, F., Surdo, P. L., Ontoria, J. M., Rowley, M., Scarpelli, R., Schultz‐Fademrecht, C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.026 · Cited by 64

Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif

Kim, M.-A., Kim, H., Brown, A. L., Lee, M.-Y., Bae, Y., Park, J., Kwak, J.-Y., Chung, J. H., & Yun, J. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.23 · Cited by 61

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo

Atsumi, A., Tomita, A., Kiyoi, H., & Naoe, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.047 · Cited by 51

Bispyridinium Dienes: Histone Deacetylase Inhibitors with Selective Activities

Pérez‐Balado, C., Nebbioso, A., Rodríguez‐Graña, P., Minichiello, A., Miceli, M., Altucci, L., & de Lera, Á. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070028m · Cited by 49

Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells

Deubzer, H. E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A. E., Schwab, M., & Witt, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.23295 · Cited by 39

HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients

Park, B. L., Kim, Y. J., Cheong, H. S., Lee, S. O., Han, C. S., Yoon, J., Park, J. H., Chang, H. S., Park, C., Lee, H.-S., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.026 · Cited by 37

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro

Deubzer, H. E., Ehemann, V., Kulozik, A. E., Westermann, F., Savelyeva, L., Kopp‐Schneider, A., Riester, D., Schwab, M., & Witt, O. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.01.002 · Cited by 30

No Association between Polymorphisms in theHistone DeacetylaseGenes and the Risk of Lung Cancer

Park, J. M., Lee, G. Y., Choi, J. E., Kang, H. G., Jang, J. S., Ick, S., Lee, E. B., Kim, S. G., Kim, C. H., Lee, W. K., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0200 · Cited by 12

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280

Oral squamous cell carcinomas: state of the field and emerging directions

Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 965

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801

The world of protein acetylation

Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 847

New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics

Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D., Han, Y., Fong, W. F., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/627375 · Cited by 750

Progress in the Research of Selective Histone Deacetylase Inhibitors

Lü, S. (2010) · The Chinese Journal of Modern Applied Pharmacy

In Silico Approaches Towards Safe Targeting of Class I Histone Deacetylases

Ganai, S. A. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6436-5_459-1 · Cited by 11

5 Histone Deacetylase Inhibitors: A Novel Class of Anti-Cancer Agents on its Way to the Market

Körner, M., & Tibes, U. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00005-7 · Cited by 13

Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer

Marcotullio, L. D., Canettieri, G., Infante, P., Greco, A., & Gulino, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.01.002 · Cited by 51

Targeting class I histone deacetylases in cancer therapy

Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 66